Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
multivalent inactivated COVID-19 vaccine
- Development stage
- Preclinical
- Lead developer
- Sinopharm
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The multivalent inactivated COVID-19 vaccine is a next-generation vaccine candidate developed by the Beijing Institute of Biological Products (BIBP), a subsidiary of Sinopharm (China National Biotec Group / CNBG). Utilizing a traditional inactivated virus platform, this vaccine incorporates multiple strains of the SARS-CoV-2 virus—typically including the ancestral strain alongside variants of concern such as Omicron—to elicit a broader and more robust immune response compared to monovalent formulations. By presenting the immune system with whole, chemically inactivated virions, the vaccine induces neutralizing antibodies against the spike protein and other structural proteins. As of the latest pipeline updates, the program is in the preclinical development stage, aimed at addressing the challenge of viral evolution and immune escape.
- Other names
- 多价新冠灭活疫苗Multivalent SARS-CoV-2 inactivated vaccine
02
Targets
E (Tick-borne encephalitis virus envelope protein)N (Nucleocapsid protein)M protein (SARS-CoV-2 membrane protein)SARS-CoV-2 spike
Beyond the preview
Go deeper on multivalent inactivated COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on multivalent inactivated COVID-19 vaccine.